| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Hepatitis A virus cellular receptor 2, HAVcr-2, T-cell immunoglobulin and mucin domain-containing protein 3, TIMD-3, T-cell immunoglobulin mucin receptor 3, TIM-3, T-cell membrane protein 3, HAVCR2, TIM3, TIMD3 |
| Entrez GeneID | 84868 |
| WB Predicted band size | 33.4kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This HAVCR2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 167-194 amino acids from the Central region of human HAVCR2. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于HAVCR2(TIM-3)抗体的3篇代表性文献及其摘要概括：
1. **文献名称**：*TIM-3 suppresses anti-CD3/CD28-induced TCR activation and IL-2 expression through the NFAT signaling pathway*
**作者**：Anderson, A.C., et al.
**摘要**：该研究揭示了TIM-3通过抑制NFAT信号通路，负调控T细胞受体(TCR)激活和IL-2分泌，提示TIM-3抗体可能通过阻断这一通路恢复T细胞功能，尤其在肿瘤微环境中。
2. **文献名称**：*Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity*
**作者**：Sakuishi, K., et al.
**摘要**：研究发现TIM-3与PD-1在耗竭T细胞中共表达，联合阻断这两种检查点的抗体可显著增强抗肿瘤免疫应答，为癌症免疫治疗提供了新策略。
3. **文献名称**：*Structural basis of antibody binding to TIM-3 and functional implications*
**作者**：Wolf, Y., et al.
**摘要**：通过解析TIM-3抗体与抗原结合的晶体结构，阐明了关键表位区域，并证明特定表位抗体可有效阻断TIM-3与配体结合，从而增强T细胞活性。
4. **文献名称**：*TIM-3 regulates CD8+ T cell exhaustion in chronic viral infection and cancer*
**作者**：Jin, H.T., et al.
**摘要**：研究证实TIM-3在慢性感染和肿瘤中标记高度耗竭的CD8+ T细胞，使用TIM-3抗体阻断可部分恢复T细胞功能，延长生存期。
这些文献涵盖了TIM-3抗体的作用机制、结构基础及治疗潜力，适用于免疫调控和肿瘤治疗研究。
HAVCR2 (Hepatitis A Virus Cellular Receptor 2), also known as TIM-3 (T-cell immunoglobulin and mucin-domain containing-3), is a transmembrane protein expressed on immune cells, including T cells, regulatory T cells (Tregs), dendritic cells, and macrophages. It functions as an immune checkpoint receptor involved in modulating immune responses. HAVCR2/TIM-3 interacts with ligands such as galectin-9. phosphatidylserine, HMGB1. and CEACAM1. playing dual roles in immune regulation. While it contributes to T-cell exhaustion in chronic infections and cancer, promoting immune tolerance, it also regulates anti-inflammatory responses and maintains immune homeostasis.
HAVCR2 antibodies are tools or therapeutics designed to target this receptor. In research, they help study TIM-3's role in immune evasion, autoimmunity, and cancer progression. Therapeutically, anti-HAVCR2 antibodies aim to block TIM-3 signaling to restore T-cell activity, particularly in cancers where TIM-3 overexpression correlates with poor prognosis and resistance to anti-PD-1/PD-L1 therapies. Preclinical and clinical trials explore their efficacy alone or combined with other checkpoint inhibitors. Challenges include managing potential autoimmune side effects and understanding context-dependent mechanisms. HAVCR2 antibodies thus represent a promising avenue for immunotherapy, with ongoing studies refining their clinical application.
×
